Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma
From the perspective of US payers, atezolizumab plus bevacizumab is not cost-effective for mRCC patients. To make this combination cost-effective in the future, the price of atezolizumab and bevacizumab needs to be reduced.
Authors
- Siying Wang (ORCID: https://orcid.org/0000-0003-0810-8828)
- Ouyang Xie
- Heng Xiang
- Chongqing Tan (ORCID: https://orcid.org/0000-0002-6007-4170)
- Meiyu Wu
- Xiaomin Wan
Institutions
- Central South University (CN)
- Xiangyang Central Hospital (CN)
- Second Xiangya Hospital of Central South University (CN)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2024-08-31
- DOI
- https://doi.org/10.1080/14737167.2024.2399246
- Citations
- 2
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.26
Funders
- National Natural Science Foundation of China